Janssen, Gilead Clear Mylan To Sell Generic HIV Drug

Law360, New York (November 9, 2017, 4:19 PM EST) -- Janssen Pharmaceutica NV on Thursday told a Delaware federal court that it has granted Mylan Pharmaceuticals Inc. a license to use eight patents tied to the HIV treatment Complera, ending an infringement suit Janssen and Gilead Sciences Inc. had filed and clearing Mylan to eventually sell a generic.

The consent judgment claims that U.S. Patent Numbers 8,841,310; 7,125,879; 8,101,629; 8,080,551; 7,399,856; 7,563,922; 8,101,752; and 8,618,291 are still valid and enforceable, but that Mylan may use them starting on an unspecified date. While Janssen owns the patents,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.